Search Results - "sodium/glucose cotransporter 2"

Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate by Kayla Chonko, Giavanna Russo-Alvarez, Diana Isaacs, Lu Wang, Amanda Soric

Connect to this object online.

Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure by Ya-Wen Lin PhD, RN, Chun-Hsiang Lin MS, MD, Cheng-Li Lin MS, Che-Huei Lin PhD, BPhar, Ming-Hung Lin PhD, BPhar

Connect to this object online.

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale by Yassin SA, Aroda VR

Connect to this object online.

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis by Mobin Mohammadtabar, Alireza Fazeli, Najmeh Parsai, Zahra Aboulfathiyarmohammadyar, Erfan Shafiei, Mohamad Khaledi, Elahe Zaremoghadam, Ali Rahnama Sisakht, Saeid Mohammadi, Hossein Mardanparvar

Connect to this object online.

Refractory wound healing and cytopenias treated with a sodium-glucose cotransporter-2 inhibitor in a patient with glucose-6-phosphatase catalytic subunit 3 deficiency by Louis Marois, MD, PhD, Caridad Le Gal, MD, Guilhem Cros, MD, Emilia Liana Falcone, MD, PhD, Hugo Chapdelaine, MD

Connect to this object online.

Remission of Proteinuria in a Patient Affected by Crescentic IgA Nephropathy with Rapidly Progressive Glomerulonephritis Treated by Sodium-Glucose Cotransporter-2 Inhibitors: Casual or Causal Relationship? by José C. De La Flor Merino, Jacqueline Apaza Chávez, Francisco Valga Amado, Francisco Díaz Crespo, Pablo Justo Avila, Alexander Marschall, Michael Cieza Terrones, Patricia Núñez Ramos, Elisa Ruiz Cicero

Connect to this object online.

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis by Glover S, Borrego ME, Ray GM, Roberts MH

Connect to this object online.

Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials by Suiyuan Hu, Chu Lin, Xiaoling Cai, Xingyun Zhu, Fang Lv, Wenjia Yang, Linong Ji

Connect to this object online.

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects by Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, Marialucia Telesca, Gabriella Bellocchio, Giuseppe Castaldo, Giuseppe Castaldo, Francesco Rossi, Antonella De Angelis, Donato Cappetta, Konrad Urbanek, Konrad Urbanek, Liberato Berrino

Connect to this object online.

Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement by Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology

Connect to this object online.

Combined Therapy of Low-Dose Angiotensin Receptor-Neprilysin Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects by Donghyun Kim, Gyuho Jang, Jaetaek Hwang, Xiaofan Wei, Hyunsoo Kim, Jinbae Son, Sang-Jae Rhee, Kyeong-Ho Yun, Seok-Kyu Oh, Chang-Myung Oh, Raekil Park

Connect to this object online.

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials by Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai, Ching-Hui Sia

Connect to this object online.

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes by Vaia Lambadiari, John Thymis, Dimitris Kouretas, Zoi Skaperda, Fotios Tekos, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou, Maria Tsoumani, Christina Chania, Konstantinos Katogiannis, George Dimitriadis, Aristotelis Bamias, Ignatios Ikonomidis

Connect to this object online.

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study by Ghazwa B. Korayem, Omar A. Alshaya, Omar A. Alshaya, Omar A. Alshaya, Albandari A. Alghamdi, Shahad S. Alanazi, Renad T. Almutib, Mahdi Alsaileek, Abdulrahman Alrashidi, Nasser Aldosari, Nader Bin Sheraim, Majed S. Al Yami, Majed S. Al Yami, Majed S. Al Yami, Omar A. Almohammed, Omar A. Almohammed

Connect to this object online.

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020 by Joshua A. Jacobs, Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ambarish Pandey, Adam P. Bress

Connect to this object online.

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study by Yen-Chieh Lee, Yen-Chieh Lee, Yaa-Hui Dong, Yaa-Hui Dong, Yaa-Hui Dong, Wei-Shun Yang, Wei-Shun Yang, Li-Chiu Wu, Jou-Wei Lin, Jou-Wei Lin, Jou-Wei Lin, Chia-Hsuin Chang, Chia-Hsuin Chang, Chia-Hsuin Chang

Connect to this object online.

Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches

Subjects: “…SGLT2 (sodium-glucose cotransporter 2) inhibitor…”
DOAB: download the publication
DOAB: description of the publication

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks by Sanbao Chai, Fengqi Liu, Zhirong Yang, Shuqing Yu, Zuoxiang Liu, Qingqing Yang, Feng Sun

Connect to this object online.

Neurotransmitter-Related Molecular Modeling Studies

Subjects: “…sodium-glucose cotransporter 2 inhibitors…”
DOAB: download the publication
DOAB: description of the publication

Drug Metabolism/Transport and Pharmacokinetics

Subjects: “…sodium-glucose cotransporter 2 (SGLT2) inhibitors…”
DOAB: download the publication
DOAB: description of the publication